🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you my dear friend Hind Rafei and thank you to my amazing mentor Dr. Katy Rezvani Katy Rezvani, M.D., Ph.D! 🎉🙏

Delighted to report that our review on NK cell bases immunotherapies is now online in Nature Reviews Cancer. Congratulations Alexander Biederstädt, MD and Tamara Laskowski. MD Anderson Cancer Center Nature Reviews Cancer #immunotherapy #NK rdcu.be/cSl3G doi.org/10.1038/s41568…

NEW content online! Natural killer cells in antitumour adoptive cell immunotherapy dlvr.it/SVT4QP

Congratulations Katy Rezvani, M.D., Ph.D Alexander Biederstädt, MD and Tamara Laskowski for a great review on NK cell based immunotherapy for cancer! A must read for a great overview of all achievements in the field! MD Anderson Cancer Center #NK #celltherapy

So humbled and honored to receive the Andrew Sabin fellowship for my research focusing on metabolically enhanced CAR-NK cells. Note to fellows/junior faculty interested in research: it’s a long and difficult journey but hard work eventually pays off. MD Anderson Cancer Center #endcancer

Incredible tour de force of NK cell therapies from our team led by Dr. Katy Rezvani Katy Rezvani, M.D., Ph.D MD Anderson Cancer Center with many exciting therapies being translated from the bench to the bedside with a true off-the-shelf approach! The future is bright! 🤩#NK #celltherapy

Great opening session of the NK cell session by ⁦Katy Rezvani, M.D., Ph.D⁩ with an exciting timeline of bench to bedside translation of NK ACT! Amazing line up of experts in the field! ⁦Katy Rezvani, M.D., Ph.D⁩ ⁦Rizwan Romee⁩ ⁦Eric Vivier⁩ Jeff Miller! ⁦MD Anderson Cancer Center⁩

Learn about how the most recent advances in gene editing toolkits converge with #cellular #immunotherapy to drive a new wave of multiplex-engineered cell therapy products for the immunotherapy of cancer. Thanks to the incredible May Daher and Gohar Manzar, MD PhD from Katy Rezvani, M.D., Ph.D.

Hot off the press: Our How I treat? article in @BloodJournal lays out promising new cell-based treatment strategies for AML post-alloHSCT. doi.org/10.1182/blood.… Thanks tons to Dr. Katy Katy Rezvani, M.D., Ph.D for helping distill decades of transplanter experience for this manuscript.

Introduction to a How I Treat series on management of high-risk patients following allogeneic transplant loom.ly/0L1J8UY

How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy loom.ly/cssOVbU

Outstanding grand rounds this morning about team science advances in tackling ovarian cancer from experts in the field! Very exciting to witness impressive translational progress in NK cell therapy for ovarian cancer presented by Dr. Katy Rezvani! Katy Rezvani, M.D., Ph.D MD Anderson Cancer Center

“We believe that the TCR NK cell approach will allow targeting of a broad range of tumor antigens," says our Dr. Katy Rezvani of a collaboration with Replay to launch a new company, Syena. Learn about it here: fal.cn/3vRpi Katy Rezvani, M.D., Ph.D #Research #EndCancer

Interesting paper in today's Blood Advances on preclinical testing that shows SUMOylation inhibitor is synergistic with proteasome inhibition in #MultipleMyeloma ashpublications.org/bloodadvances/…

Mesmerizing talk by Katy Rezvani, M.D., Ph.D at #EBMT2023 showcasing the multiple NK engineering platforms to enhance NK anti-tumor activity, with new exciting and promising early clinical data of CD70 targeting CAR-NK cells! #NK #CAR #celltherapy

This morning at #AACR25, our Dr. Katy Rezvani shared an overview of her team’s wide-ranging CAR NK cell platform targeting hematological malignancies and solid tumors, leading to 12 ongoing clinical trials. Katy Rezvani, M.D., Ph.D AACR #EndCancer

Congratulations to Alexander Biederstädt, MD on an outstanding presentation #AACR25, showcasing a novel platform for genome-wide CRISPR screening in primary human CAR NK cells. So proud of your achievements and excited to watch your continued impact in the field. #NKcells MD Anderson Cancer Center

Headed back to HTX from Chicago and this is what I saw at O'Hare Intl. Airport. The most powerful brand in cancer care - the global leader:

Please check out our paper published today in Nature that identifies CREM as a key checkpoint limiting CAR NK cell function.CRISPR knockout of CREM significantly enhanced anti-tumor activity, implicating a broader role in NK cell regulation. Huge congrats to @hindrafei and our

Back from an amazing #NK2025! 🧬✨ Honored to present our work on genome-wide CRISPR screens to boost CAR-NK cell potency💥Immensely grateful to my incredible mentor, Katy Rezvani, M.D., Ph.D 🙏🌟 for her support and to the #SocietyforNaturalImmunity for the travel award🙌 #NKcells #ACT